Pardes Biosciences, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 38.52 million. Basic loss per share from continuing operations was USD 10.13.
Pardes Biosciences, Inc.
Equities
PRDS
US69945Q1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |